Featured Publications
Cost-Effectiveness of Aspirin for Extended Venous Thromboembolism Prophylaxis After Major Surgery for Inflammatory Bowel Disease
Leeds IL, Sklow B, Gorgun E, Liska D, Lightner AL, Hull TL, Steele SR, Holubar SD. Cost-Effectiveness of Aspirin for Extended Venous Thromboembolism Prophylaxis After Major Surgery for Inflammatory Bowel Disease. Journal Of Gastrointestinal Surgery 2022, 26: 1275-1285. PMID: 35277799, DOI: 10.1007/s11605-022-05287-z.Peer-Reviewed Original ResearchMeSH KeywordsAftercareAnticoagulantsAspirinCost-Benefit AnalysisEnoxaparinHumansInflammatory Bowel DiseasesPatient DischargeVenous ThromboembolismConceptsInflammatory bowel disease surgeryLow-dose aspirinQuality-adjusted life yearsThromboembolism prophylaxisDisease surgeryUnfavorable incremental cost-effectiveness ratiosLife yearsExtended venous thromboembolism prophylaxisPost-discharge event ratePocket costsIncremental cost-effectiveness ratioVenous thromboembolism prophylaxisEfficacy of aspirinInflammatory bowel diseaseMedian hospital costsMonte Carlo probabilistic sensitivity analysisCost-effectiveness ratioProbabilistic sensitivity analysesDecision analysis modelEnoxaparin regimenThromboembolism ratesVenous thromboembolismBowel diseaseColorectal surgeryCase patientsOn All Accounts: Cost-Effectiveness Analysis of Limited Preoperative Optimization Efforts Before Colon Cancer Surgery
Leeds IL, Drabo EF, Lehmann LS, Safar B, Johnston FM. On All Accounts: Cost-Effectiveness Analysis of Limited Preoperative Optimization Efforts Before Colon Cancer Surgery. Diseases Of The Colon & Rectum 2021, 64: 744-753. PMID: 33955409, PMCID: PMC8835996, DOI: 10.1097/dcr.0000000000001926.Peer-Reviewed Original ResearchConceptsCost-effectiveness analysisProbabilistic sensitivity analysesNet monetary benefitIncremental cost-effectiveness ratioTotal costCost-effectiveness ratioMonetary benefitsSensitivity analysisBreakeven costDominant strategyEconomic costsDecision analysis methodologyCostHypothetical scenariosAlto riesgoEl análisisAnálisisEconómicoBenefitsAnalysis methodologyReducción
2019
Cost-Benefit Limitations of Extended, Outpatient Venous Thromboembolism Prophylaxis Following Surgery for Crohn's Disease.
Leeds IL, DiBrito SR, Canner JK, Haut ER, Safar B. Cost-Benefit Limitations of Extended, Outpatient Venous Thromboembolism Prophylaxis Following Surgery for Crohn's Disease. Diseases Of The Colon & Rectum 2019, 62: 1371-1380. PMID: 31596763, PMCID: PMC6788772, DOI: 10.1097/dcr.0000000000001461.Peer-Reviewed Original ResearchConceptsVenous thromboembolism prophylaxisMultivariable probabilistic sensitivity analysesCrohn's diseaseHigh thrombotic riskProbabilistic sensitivity analysesThromboembolism prophylaxisExtended prophylaxisSurgical populationAbdominal surgeryThrombotic eventsUtility weightsSocietal perspectiveProductivity costsLifetime horizonIncremental costConventional measuresEnfermedad de CrohnPostoperative venous thromboembolismLow absolute riskHigh-risk individualsLos costosDecision tree modelDecision analysisRange of scenariosTotal costJustifying Total Costs of Extended Venothromboembolism Prophylaxis After Colorectal Cancer Surgery
Leeds IL, Canner JK, DiBrito SR, Safar B. Justifying Total Costs of Extended Venothromboembolism Prophylaxis After Colorectal Cancer Surgery. Journal Of Gastrointestinal Surgery 2019, 24: 677-687. PMID: 30945086, PMCID: PMC6776724, DOI: 10.1007/s11605-019-04206-z.Peer-Reviewed Original ResearchMeSH KeywordsAnticoagulantsColorectal NeoplasmsCost-Benefit AnalysisHemorrhageHumansQuality-Adjusted Life YearsVenous ThromboembolismConceptsVTE event ratesColorectal cancer surgeryCancer surgeryDecision analysis modelEvent ratesCancer surgical patientsHigher VTE ratesHigh-risk patientsCase fatality ratePayer administrative databaseOutcomes of interestProbabilistic sensitivity analysesBackgroundCurrent guidelinesBleeding eventsExtended prophylaxisProvider uptakeVTE ratesVTE eventsMost patientsPostoperative dischargeSurgical patientsRisk stratificationAdministrative databasesClinical guidanceNational guidelines
2018
Cost Effectiveness of Meningococcal Serogroup B Vaccination in College-Aged Young Adults
Leeds IL, Namasivayam V, Bamogo A, Sankhla P, Thayer WM. Cost Effectiveness of Meningococcal Serogroup B Vaccination in College-Aged Young Adults. American Journal Of Preventive Medicine 2018, 56: 196-204. PMID: 30573332, PMCID: PMC6340776, DOI: 10.1016/j.amepre.2018.09.020.Peer-Reviewed Original ResearchConceptsQuality-adjusted life yearsMultivariable probabilistic sensitivity analysesUniversal vaccinationProbabilistic sensitivity analysesLife yearsSerogroup BSocietal perspectiveYoung adultsHealth sector perspectiveUniversal vaccination strategyNeisseria meningitidis serogroup BN. meningitidis serogroup BCost effectivenessU.S. vaccineB vaccinationMeningococcal infectionVaccination strategiesSpecific vaccinesVaccinationSensitivity analysisIncremental costOutbreak responseSector perspectiveCollege entryCommon form